Thomas Marron, MD, PhD, on the Next Steps in Phase 1 Trial Investigating PGV-001

Marron discussed the next steps to a trial of PGV-001, specifically centered around determining the immunogenicity of vaccinated patients against their antigens.

Thomas Marron, MD, PhD, of the Icahn School of Medicine at Mount Sinai, spoke with CancerNetwork® at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021 about the next steps in a phase 1 trial of PGV-001, focusing on the immunogenicity of the cohort of vaccinated patients against their antigens.

Transcription:

Right now, we’re in the process of measuring the immunogenicity, basically the degree to which we successfully vaccinated these patients against their antigens. And we’re also looking at subsequent biopsies from patients who did have recurrent disease after the vaccine to see if there [are] any changes in the epitopes that are present or the antigens that are present in those recurrent tumors. In the poster, we show some data demonstrating that we did successfully prime a T-cell response, both the CD4 and the CD8 T-cell responses, against the neoantigens with which we vaccinated. And we’re hoping to see similar results as we continue our immune monitoring of the blood samples from the remaining patients.

Reference:

Marron TU, Saxena M, Bhardwaj N, et al. An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001). Presented at: AACR Annual Meeting 2021; April 10-15, 2021; virtual. Abstract LB048.